Biologics Forum: Tips and Tools for Successful Immunotherapy Bioassay Development

Tuesday, April 23, 2019

Mechanism of action (MOA)-based bioassays are a critical component of biologics drug development. However, establishing a functional bioassay that meets the regulatory guidelines for use in potency determination and lot release can be challenging. Join our panel of bioassay experts for a live discussion on bioassay design and selection, assay optimization, and bioassay qualification for potency lot release.

Submit a question with your registration by April 12 and have your question answered in the presentation. 

You will also have the opportunity to submit questions during the live Q&A session. Registration and attendance will provide access to additional resources that address your bioassay needs.

View Webinar Recording 

 

 Zhijie Jey Cheng, PhD 
Jey Cheng is an R&D Group Leader in bioassay development at Promega Corporation. Dr. Cheng’s group focuses on developing MOA-based reporter gene bioassays using engineered cell lines to quantitatively measure the potency of biologic drugs developed for cancer immunotherapy. Prior to joining Promega, Jey was an assistant professor of Biochemistry & Molecular Biology at Mayo Clinic College of Medicine, where she also completed postdoctoral Kendall-Mayo Fellowship in Biochemistry. She received her PhD in Cell Biology from Shanghai Institute of Cell Biology through a Joint PhD program by German Max-Planck Society and Chinese Academy of Sciences.


 Manuela Grassi, PhD 
Manuela is Group Leader of Cell Manufacturing at Promega Corporation and responsible for the manufacturing of bioassay cells. Prior to joining Promega, Manuela worked 10+ years for a CRO focusing on functional cell-based assays for vaccine and drug development. In that role, she gained extensive experience in bioassay development, validation and associated lot release and stability testing for biologics in a GMP environment. Manuela received her PhD in Microbiology from the University of Brescia (Italy) and performed her graduate research as a visiting scientist at the Institute of Human Virology at the University of Maryland.


 Richard Somberg, PhD 
Richard Somberg is Director of the Pharma/Biotech Business Unit, focusing on building strategic relationships through technical introductions on early access technologies, custom assay services and collaborative support. Prior to Promega, Dr. Somberg worked at Life Technologies where he led product development and service efforts in biochemical and cell-based assays for key target classes in drug discovery. He received his PhD in immunology from Purdue University and completed post-doctoral studies at the University of Pennsylvania.